Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
Journal
The Lancet. Oncology
Journal Volume
24
Journal Issue
8
Date Issued
2023-08
Author(s)
Pant, Shubham
Schuler, Martin
Iyer, Gopa
Witt, Olaf
Doi, Toshihiko
Qin, Shukui
Tabernero, Josep
Reardon, David A
Massard, Christophe
Minchom, Anna
Lugowska, Iwona
Carranza, Omar
Arnold, Dirk
Gutierrez, Martin
Winter, Helen
Stuyckens, Kim
Crow, Lauren
Najmi, Saltanat
Hammond, Constance
Thomas, Shibu
Santiago-Walker, Ademi
Triantos, Spyros
Sweiti, Hussein
Loriot, Yohann
Abstract
FGFR alterations are reported across various malignancies and might act as oncogenic drivers in multiple histologies. Erdafitinib is an oral, selective pan-FGFR tyrosine kinase inhibitor with activity in FGFR-altered advanced urothelial carcinoma. We aimed to evaluate the safety and activity of erdafitinib in previously treated patients with FGFR-altered advanced solid tumours.
SDGs
Type
journal article